Table 1 (for time-overlapping scenario 1).
site | APC1 | APC2 | naive T-test | Corrected Z-test | estimated residual variance |
---|---|---|---|---|---|
All Malignant Cancers | −0.5 | −0.5 | 0.030 | 0.050 | 5.71E-05 |
−0.5 | −0.3 | 0.940 | 0.960 | 5.68E-05 | |
−0.5 | −0.1 | 0.99 | 1.00 | 5.63E-05 | |
−0.3 | −0.3 | 0.032 | 0.047 | 5.63E-05 | |
−0.3 | −0.1 | 0.930 | 0.960 | 5.59E-05 | |
−0.3 | 0.1 | 0.99 | 1.00 | 5.56E-05 | |
−0.1 | −0.1 | 0.032 | 0.048 | 5.55 E-05 | |
−0.1 | 0.1 | 0.94 | 0.96 | 5.52E-05 | |
−0.1 | 0.3 | 0.99 | 1.00 | 5.49E-05 | |
0.1 | 0.1 | 0.030 | 0.050 | 5.47E-05 | |
0.1 | 0.3 | 0.94 | 0.96 | 5.44E-05 | |
0.1 | 0.5 | 0.99 | 1.00 | 5.44E-05 | |
0.3 | 0.3 | 0.032 | 0.050 | 5.40E-05 | |
0.3 | 0.5 | 0.94 | 0.96 | 5.36E-05 | |
0.3 | 0.7 | 0.99 | 1.00 | 5.33E-05 | |
0.5 | 0.5 | 0.031 | 0.050 | 5.32E-05 | |
0.5 | 0.7 | 0.94 | 0.97 | 5.26E-05 | |
0.5 | 1.0 | 0.99 | 1.00 | 5.26E-05 | |
Prostate Cancer | −0.5 | −0.5 | 0.031 | 0.050 | 0.000480 |
−0.5 | −0.3 | 0.188 | 0.242 | 0.000477 | |
−0.5 | −0.1 | 0.655 | 0.716 | 0.000475 | |
−0.5 | 0.1 | 0.94 | 0.97 | 0.000472 | |
−0.3 | −0.3 | 0.031 | 0.050 | 0.000474 | |
−0.3 | −0.1 | 0.191 | 0.245 | 0.000471 | |
−0.3 | 0.1 | 0.660 | 0.721 | 0.000468 | |
−0.3 | 0.3 | 0.95 | 0.97 | 0.000466 | |
−0.1 | −0.1 | 0.031 | 0.049 | 0.000467 | |
−0.1 | 0.1 | 0.193 | 0.247 | 0.000465 | |
−0.1 | 0.3 | 0.665 | 0.724 | 0.000462 | |
−0.1 | 0.5 | 0.95 | 0.97 | 0.000459 | |
0.1 | 0.1 | 0.031 | 0.049 | 0.000461 | |
0.1 | 0.3 | 0.196 | 0.250 | 0.000458 | |
0.1 | 0.5 | 0.670 | 0.727 | 0.000456 | |
0.1 | 0.7 | 0.953 | 0.970 | 0.000453 | |
0.3 | 0.3 | 0.031 | 0.049 | 0.000455 | |
0.3 | 0.5 | 0.198 | 0.250 | 0.000452 | |
0.3 | 0.7 | 0.673 | 0.733 | 0.000450 | |
0.3 | 1.0 | 0.990 | 0.994 | 0.000446 | |
0.5 | 0.5 | 0.032 | 0.050 | 0.000449 | |
0.5 | 0.7 | 0.200 | 0.253 | 0.000446 | |
0.5 | 1.0 | 0.860 | 0.894 | 0.000443 |